K C Lakshmaiah

Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study

Timothy Iveson, Ross C. Donehower, S. Tjulandin et al. · The Lancet Oncology · 2014 · 260 citations

Gastrointestinal Oncology, Medicine, Pathology +8

Delays in diagnosis and treatment of breast cancer: a multinational analysis

Jacek Jassem, Vahit Özmen, Florin Bacanu et al. · European Journal of Public Health · 2013 · 145 citations · Full text

Febrile Neutropenia in Hematological Malignancies: Clinical and Microbiological Profile and Outcome in High Risk Patients

K C Lakshmaiah, Abhayakumar S Malabagi, Rachan Shetty et al. · Journal of Laboratory Physicians · 2015 · 52 citations · Full text

Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study

Véronique Dièras, Hans Wildiers, Jacek Jassem et al. · The Breast · 2015 · 49 citations · Full text

Metastatic Breast Cancer, Breast Oncology, Medicine +7

Clinicopathological Profile of Pure Neuroendocrine Neoplasms of the Esophagus: A South Indian Center Experience

Govind Babu Kanakasetty, L. Dasappa, K C Lakshmaiah et al. · Journal of Oncology · 2016 · 27 citations · Full text

Esophageal Cancer, Gastroenterology, Pathology +16